z-logo
open-access-imgOpen Access
Integrin Signaling in Cancer Cell Survival and Chemoresistance
Author(s) -
Fawzi Aoudjit,
Kristiina Vuori
Publication year - 2012
Publication title -
chemotherapy research and practice
Language(s) - English
Resource type - Journals
eISSN - 2090-2115
pISSN - 2090-2107
DOI - 10.1155/2012/283181
Subject(s) - integrin , medicine , cancer , cancer research , cancer cell , extracellular matrix , cancer stem cell , signal transduction , cell , chemotherapy , apoptosis , immunology , receptor , biology , microbiology and biotechnology , genetics , biochemistry
Resistance to apoptosis and chemotherapy is a hallmark of cancer cells, and it is a critical factor in cancer recurrence and patient relapse. Extracellular matrix (ECM) via its receptors, the integrins, has emerged as a major pathway contributing to cancer cell survival and resistance to chemotherapy. Several studies over the last decade have demonstrated that ECM/integrin signaling provides a survival advantage to various cancer cell types against numerous chemotherapeutic drugs and against antibody therapy. In this paper, we will discuss the major findings on how ECM/integrin signaling protects tumor cells from drug-induced apoptosis. We will also discuss the potential role of ECM in malignant T-cell survival and in cancer stem cell resistance. Understanding how integrins and their signaling partners promote tumor cell survival and chemoresistance will likely lead to the development of new therapeutic strategies and agents for cancer treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom